Abstract
The tetracycline-controlled Tet-Off and Tet-On gene expression systems are used to regulate the activity of genes in eukaryotic cells in diverse settings, varying from basic biological research to biotechnology and gene therapy applications. These systems are based on regulatory elements that control the activity of the tetracycline-resistance operon in bacteria. The Tet-Off system allows silencing of gene expression by administration of tetracycline (Tc) or tetracycline-derivatives like doxycycline (dox), whereas the Tet-On system allows activation of gene expression by dox. Since the initial design and construction of the original Tet-system, these bacterium-derived systems have been significantly improved for their function in eukaryotic cells. We here review how a dox-controlled HIV-1 variant was designed and used to greatly improve the activity and dox-sensitivity of the rtTA transcriptional activator component of the Tet-On system. These optimized rtTA variants require less dox for activation, which will reduce side effects and allow gene control in tissues where a relatively low dox level can be reached, such as the brain.
Keywords: Tet-On system, Tet-Off system, Transcription regulation, Doxycycline, Gene expression, rtTA, tTA, TetR.
Current Gene Therapy
Title:Tet-On Systems For Doxycycline-inducible Gene Expression
Volume: 16 Issue: 3
Author(s): Atze T. Das, Liliane Tenenbaum and Ben Berkhout
Affiliation:
Keywords: Tet-On system, Tet-Off system, Transcription regulation, Doxycycline, Gene expression, rtTA, tTA, TetR.
Abstract: The tetracycline-controlled Tet-Off and Tet-On gene expression systems are used to regulate the activity of genes in eukaryotic cells in diverse settings, varying from basic biological research to biotechnology and gene therapy applications. These systems are based on regulatory elements that control the activity of the tetracycline-resistance operon in bacteria. The Tet-Off system allows silencing of gene expression by administration of tetracycline (Tc) or tetracycline-derivatives like doxycycline (dox), whereas the Tet-On system allows activation of gene expression by dox. Since the initial design and construction of the original Tet-system, these bacterium-derived systems have been significantly improved for their function in eukaryotic cells. We here review how a dox-controlled HIV-1 variant was designed and used to greatly improve the activity and dox-sensitivity of the rtTA transcriptional activator component of the Tet-On system. These optimized rtTA variants require less dox for activation, which will reduce side effects and allow gene control in tissues where a relatively low dox level can be reached, such as the brain.
Export Options
About this article
Cite this article as:
Das T. Atze, Tenenbaum Liliane and Berkhout Ben, Tet-On Systems For Doxycycline-inducible Gene Expression, Current Gene Therapy 2016; 16 (3) . https://dx.doi.org/10.2174/1566523216666160524144041
DOI https://dx.doi.org/10.2174/1566523216666160524144041 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interaction of Endocannabinoid Receptors with Biological Membranes
Current Medicinal Chemistry The Urokinase Receptor Interactome
Current Pharmaceutical Design Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance
Current Pharmaceutical Design Role of GSK-3 in Cardiac Health: Focusing on Cardiac Remodeling and Heart Failure
Current Drug Targets Endocannabinoid Signaling in Midbrain Dopamine Neurons: More than Physiology?
Current Neuropharmacology Autism, Mitochondria and Polybrominated Diphenyl Ether Exposure
CNS & Neurological Disorders - Drug Targets Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Evaluation of Dendrimer Safety and Efficacy through Cell Line Studies
Current Drug Targets Amyloid Beta: The Alternate Hypothesis
Current Alzheimer Research Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
CNS & Neurological Disorders - Drug Targets Regenerative Medicine: Does Erythropoietin have a Role?
Current Pharmaceutical Design Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers
Current Pharmaceutical Design Mitophagy in Neurodegeneration: An Opportunity for Therapy?
Current Drug Targets Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets Mitochondrial Dysfunction and Oxidative Stress in Insulin Resistance
Current Pharmaceutical Design The Role of Sodium Channels in the Mechanism of Action of Antidepressants and Mood Stabilizers
Current Drug Targets Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Current Pharmaceutical Design Tamarix articulata (T. articulata) - An Important Halophytic Medicinal Plant with Potential Pharmacological Properties
Current Pharmaceutical Biotechnology microRNAs: Small Molecules with a Potentially Role in Oral Squamous Cell Carcinoma
Current Pharmaceutical Design